Read more
Informationen zum Autor Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson’s disease. He has spent the major part of his career at King’s College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King’s College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders. Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson’s disease patient-carer groups across the UK. Klappentext Neuroscience Perspectives provides multidisciplinary reviews of topics in one of the most diverse and rapidly advancing fields in the life sciences. Whether you are a new recruit to neuroscience, or an established expert, look to this series for 'one-stop' sources of the historical, physiological, pharmacological, biochemical, molecular biological and therapeutic aspects of chosen research areas. The sigma receptor was originally thought to be a subset of the opioid receptor family, and it is less than 10 years since it was recognized that this receptor represents unique binding sites in mammalian brain and peripheral organs, distinct from any other known neurotransmitter receptor. Since the sigma receptors exhibit high affinity for members of diverse classes of psychotropic drugs, and have been postulated to be involved in various central nervous disorders, neuroscientists have demonstrated a great deal of interest in the elucidation of these receptor sites and their biological relevance. Relatively little is known about the precise role of sigma receptors in normal brain function and in CNS disorders, despite an overwhelming research effort. This research has resulted in many controversies, some of which have been reconciled while others have not. This volume aims to update the reader on the current situation, and deals with the potential functional significance of these receptors in the brain and peripheral organs and, where appropriate, makes reference to the clinical potential of these sites. Zusammenfassung This volume will cover the historical background of the subject! together with the physiological! molecular biological and pharmacological aspects! with a discussion on the concept of sigma receptors subtypes and their postulated relevance for CNS disorders. Inhaltsverzeichnis Dedication. Contributors. Series Preface. Preface. Historical Perspective: Evolution of the Concept of Sigma Receptor. Sigma Receptors in the Central Nervous System and the Periphery. Structure-Activity Relationships and Evolution of Sigma Receptor Ligands (1976-present). Multiple Sigma Binding Sites i...
List of contents
Dedication.
Contributors.
Series Preface.
Preface.
Historical Perspective: Evolution of the Concept of Sigma Receptor.
Sigma Receptors in the Central Nervous System and the Periphery.
Structure-Activity Relationships and Evolution of Sigma Receptor Ligands (1976-present).
Multiple Sigma Binding Sites in the Brain.
Interaction of Sigma Receptors with Signal Transduction Pathways and Effects on Second Messengers.
Recent Evidence for Endogenous Substance(s) for Sigma Receptors.
Potential Therapeutic Application of Sigma Receptor Antagonists.
Role of Sigma Receptors in Brain Mechanisms of Movement.
Imaging Sigma Receptors and Cerebral Responses to Sigma Drugs.
Effects of Cytochrome P-450 Ligands on the Binding of [3H]dextromethorphan and Sigma Ligands to Guinea Pig Brain.
Putative Interactions Between Sigma Binding Sites and Neuropeptide Y.
Role of Sigma Binding Sites in the Modulation of Endocrine and Immune Functions.
The Sigma Receptor: Concluding Remarks/Future Vistas.
Index.
